The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
More than three in five (63%) people in the UK experience barriers to health inclusion People in UK, Canada and France face the longest waiting times to...
The assembly of the chromosomes, and a set of related biological insights, are among the findings published online November 8 in 10 papers in the journals ...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
Historical Perspective Traditionally, the Middle East's economy has been heavily reliant on its vast reserves of oil and natural gas. However, the region'...
Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with IS...
In the world of biotechnology and pharmaceuticals, innovation is the lifeblood of progress. And in the picturesque Basel area, this spirit of innovation is...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines...
The first part of the influential CPHI Annual Report predicts sizeable progress ahead for AI’s use in pharma, as despite the wider excitement around ...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
“We took a big step forward in our ongoing commitment to deliver sustainable solutions to our customers, quantifying the impact of our proprietary ap...
Researchers found that fluid therapy guided by non-invasive and continuous PVi can reduce cardiopulmonary complications and infusion. Masimo (NASD...
One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...
© 2025 Biopharma Boardroom. All Rights Reserved.
